WO2008132846A1 - 三環性ヘテロアリール化合物 - Google Patents
三環性ヘテロアリール化合物 Download PDFInfo
- Publication number
- WO2008132846A1 WO2008132846A1 PCT/JP2008/001073 JP2008001073W WO2008132846A1 WO 2008132846 A1 WO2008132846 A1 WO 2008132846A1 JP 2008001073 W JP2008001073 W JP 2008001073W WO 2008132846 A1 WO2008132846 A1 WO 2008132846A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chloro
- benzoxazepin
- ethoxyphenyl
- triazolo
- trifluoromethyl
- Prior art date
Links
- -1 heteroaryl compound Chemical class 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- JODVMENJEDBMAD-CRAIPNDOSA-N 2-[(4r,6s)-8-chloro-6-(2-chloro-3-ethoxyphenyl)-1-(trifluoromethyl)-4,6-dihydro-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetic acid Chemical compound CCOC1=CC=CC([C@@H]2C3=CC(Cl)=CC=C3N3C(=NN=C3[C@@H](CC(O)=O)O2)C(F)(F)F)=C1Cl JODVMENJEDBMAD-CRAIPNDOSA-N 0.000 abstract 1
- OPXIOJIASVSNJR-PXDATVDWSA-N 2-[1-[2-[(4r,6s)-8-chloro-6-(2-chloro-3-ethoxyphenyl)-1-(trifluoromethyl)-4,6-dihydro-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]piperidin-4-yl]acetic acid Chemical compound CCOC1=CC=CC([C@@H]2C3=CC(Cl)=CC=C3N3C(=NN=C3[C@@H](CC(=O)N3CCC(CC(O)=O)CC3)O2)C(F)(F)F)=C1Cl OPXIOJIASVSNJR-PXDATVDWSA-N 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 108010022535 Farnesyl-Diphosphate Farnesyltransferase Proteins 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 206010068961 Hypo HDL cholesterolaemia Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 102100037997 Squalene synthase Human genes 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
スクアレン合成酵素阻害作用、コレステロール合成阻害作用を示し、ヒトを含む哺乳動物のための高コレステロール血症、高トリグリセライド血症、低ＨＤＬ血症等の高脂血症及び／または動脈硬化症の予防及び／または治療薬等の医薬として有用な化合物の提供。 （１）２－［（４Ｒ，６Ｓ）－８－クロロ－６－（２－クロロ－３－エトキシフェニル）－１－（トリフルオロメチル）－４Ｈ，６Ｈ－［１，２，４］トリアゾロ［４，３－ａ］［４，１］ベンゾオキサゼピン－４－イル］アセティック アシッド （２）２－（１－｛２－［（４Ｒ，６Ｓ）－８－クロロ－６－（２－クロロ－３－エトキシフェニル）－１－（トリフルオロメチル）－４Ｈ，６Ｈ－［１，２，４］トリアゾロ［４，３－ａ］［４，１］ベンゾオキサゼピン－４－イル］アセチル｝－４－ピペリジニル）アセティック アシッド等の特定化合物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007115164A JP2010150142A (ja) | 2007-04-25 | 2007-04-25 | 三環性ヘテロアリール化合物 |
| JP2007-115164 | 2007-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008132846A1 true WO2008132846A1 (ja) | 2008-11-06 |
Family
ID=39925317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2008/001073 WO2008132846A1 (ja) | 2007-04-25 | 2008-04-24 | 三環性ヘテロアリール化合物 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP2010150142A (ja) |
| TW (1) | TW200846007A (ja) |
| WO (1) | WO2008132846A1 (ja) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010041726A1 (ja) * | 2008-10-10 | 2010-04-15 | 第一三共株式会社 | 置換三環性ヘテロアリール化合物 |
| EP2567959A1 (en) | 2011-09-12 | 2013-03-13 | Sanofi | 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5505135B2 (ja) | 2010-06-30 | 2014-05-28 | ソニー株式会社 | 画像処理装置、画像処理方法、および、プログラム |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6187684A (ja) * | 1984-10-01 | 1986-05-06 | ベーリンガー インゲルハイム コマンデイツト ゲゼルシヤフト | ジアゼピン含有医薬組成物 |
| JPS62240686A (ja) * | 1986-04-01 | 1987-10-21 | ベ−リンガ− インゲルハイム コマンデイツト ゲゼルシヤフト | １、４−ジアゼピン化合物 |
| WO1993007129A1 (fr) * | 1991-10-11 | 1993-04-15 | Yoshitomi Pharmaceutical Industries, Ltd. | Medicament utilise pour traiter l'osteoporose et compose de diazepine |
| WO2005012272A1 (ja) * | 2003-08-01 | 2005-02-10 | Takeda Pharmaceutical Company Limited | ベンズオキサゼピン系化合物 |
| WO2005068472A1 (de) * | 2004-01-14 | 2005-07-28 | Bayer Healthcare Ag | Tricyclische benzazepin-derivate als squalene synthase inhibitoren zur behandlung von kardiovaskulären erkrankungen |
| WO2007055093A1 (ja) * | 2005-10-21 | 2007-05-18 | Daiichi Sankyo Company, Limited | 三環性化合物 |
-
2007
- 2007-04-25 JP JP2007115164A patent/JP2010150142A/ja active Pending
-
2008
- 2008-04-24 WO PCT/JP2008/001073 patent/WO2008132846A1/ja active Application Filing
- 2008-04-24 TW TW097115140A patent/TW200846007A/zh unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6187684A (ja) * | 1984-10-01 | 1986-05-06 | ベーリンガー インゲルハイム コマンデイツト ゲゼルシヤフト | ジアゼピン含有医薬組成物 |
| JPS62240686A (ja) * | 1986-04-01 | 1987-10-21 | ベ−リンガ− インゲルハイム コマンデイツト ゲゼルシヤフト | １、４−ジアゼピン化合物 |
| WO1993007129A1 (fr) * | 1991-10-11 | 1993-04-15 | Yoshitomi Pharmaceutical Industries, Ltd. | Medicament utilise pour traiter l'osteoporose et compose de diazepine |
| WO2005012272A1 (ja) * | 2003-08-01 | 2005-02-10 | Takeda Pharmaceutical Company Limited | ベンズオキサゼピン系化合物 |
| WO2005068472A1 (de) * | 2004-01-14 | 2005-07-28 | Bayer Healthcare Ag | Tricyclische benzazepin-derivate als squalene synthase inhibitoren zur behandlung von kardiovaskulären erkrankungen |
| WO2007055093A1 (ja) * | 2005-10-21 | 2007-05-18 | Daiichi Sankyo Company, Limited | 三環性化合物 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010041726A1 (ja) * | 2008-10-10 | 2010-04-15 | 第一三共株式会社 | 置換三環性ヘテロアリール化合物 |
| EP2567959A1 (en) | 2011-09-12 | 2013-03-13 | Sanofi | 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010150142A (ja) | 2010-07-08 |
| TW200846007A (en) | 2008-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1773768B8 (en) | Pyrrole derivatives as pharmaceutical agents | |
| ZA200708753B (en) | Biocompatible polymer compounds for medicinal formulations | |
| WO2006126082A3 (en) | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors | |
| DE502007001453D1 (de) | 4,5-diphenyl-pyrimidinyl substituierte carbonsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| IL202248A (en) | Aster 4– (3-Methoxy-4-Chloro-Phenyl) Piprazine-1-Il of Acid 3– (Imidazol-2-Il) -Pyrazolo] 4,3– [b Pyridine – 1-Acetic, Methods of preparation and use in preparation of medicinal products | |
| WO2008132846A1 (ja) | 三環性ヘテロアリール化合物 | |
| WO2008061671A3 (en) | Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels | |
| AU2003233966A1 (en) | Analogous compounds of strobilurines and their use as acaricides and insecticides | |
| WO2008039894A3 (en) | Atorvastatin pharmaceutical compositions | |
| ZA200809206B (en) | Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled by precipitation and pharmaceutical formulations containing same | |
| AU2003272198A1 (en) | Storage of blood | |
| AU2007271980A8 (en) | Use of Fosfluridine Tidoxil (FT) for the treatment of intraepithelial proliferative diseases | |
| AU2002356423A1 (en) | Process for the preparation of amorphous atorvastatin calcium | |
| EP1779156A4 (en) | Uv barrier formulation for polyesters | |
| WO2006002203A8 (en) | Methods and compositions for the treatment of polycystic diseases | |
| AU2001260254A1 (en) | Process for the preparation of halogenated hydroxydiphenyl compounds | |
| AU2003283153A1 (en) | Pharmaceutical compositions for the treatment of urinary incontinence | |
| WO2004082591A8 (en) | Pharmaceutical composition for treatment of diabetes mellitus | |
| HK1104497A (en) | Polymers useful as medical materials | |
| HK1104496A (en) | Polymers useful as medical materials | |
| HK1102816A (en) | Novel piperidine derivative for the treatment of depression | |
| AU2004903986A0 (en) | Compounds for the Treatment of Vascular Diseases | |
| HK1084661A (zh) | 药学组合物的羧酸酯 | |
| AU2003300147A1 (en) | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process | |
| HK1100341A (en) | Therapeutic compounds: pyridine as scaffold |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08751598 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08751598 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |